BACKGROUND. People who stop consuming caffeine may have symptoms, but the incidence and severity of caffeine withdrawal are not known. This study was performed to determine the effects in the general population of ending one's dietary intake of caffeine. METHODS. We studied 62 normal adults whose intake of caffeine was low to moderate (mean amount, 235 mg--the equivalent of 2.5 cups of coffee--per day). They completed questionnaires about symptoms and tests of their mood and performance when consuming their normal diets (base-line period) and at the end of each of two two-day periods during which they consumed caffeine-free diets and under double-blind conditions received capsules containing placebo (placebo period) or caffeine (caffeine period) in amounts equal to their daily caffeine consumption. RESULTS. More subjects had abnormally high Beck Depression Inventory scores (11 percent), high scores on the trait scale of the State-Trait Anxiety Inventory (8 percent), low vigor scores (11 percent) and high fatigue scores (8 percent) on the Profile of Mood States, and moderate or severe headache (52 percent) during the placebo period than during either the base-line period (2, 0, 0, 0, and 2 percent, respectively; P less than 0.05) or the caffeine period (3, 2, 2, 0, and 6 percent; P less than 0.05). More subjects reported unauthorized use of medications during the placebo period (13 percent) than during the caffeine period (2 percent, P = 0.017). Performance of a tapping task was slower during the placebo period than during the base-line and caffeine periods (P less than 0.01). CONCLUSIONS. Persons who consume low or moderate amounts of caffeine may have a withdrawal syndrome after their daily consumption of caffeine ceases.
Source Information
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224.
This article has been cited by other articles:
Bigal, M. E., Lipton, R. B.
(2008). Clinical course in migraine: Conceptualizing migraine transformation. Neurology
71: 848-855
[Abstract][Full Text]
Lieberman, H. R.
(2007). Hydration and Cognition: A Critical Review and Recommendations for Future Research. J. Am. Coll. Nutr.
26: 555S-561S
[Abstract][Full Text]
Nassr, N., Lahu, G., Hunnemeyer, A., von Richter, O., Knoerzer, D., Reutter, F., Zech, K., Hermann, R.
(2007). Magnesium Hydroxide/Aluminium Hydroxide-Containing Antacid Does Not Affect the Pharmacokinetics of the Targeted Phosphodiesterase 4 Inhibitor Roflumilast. J Clin Pharmacol
47: 660-666
[Full Text]
Booij, L., Van der Does, A. J. W., Haffmans, P. M. J., Riedel, W. J., Fekkes, D., Blom, M. J. B.
(2005). The effects of high-dose and low-dose tryptophan depletion on mood and cognitive functions of remitted depressed patients. J Psychopharmacol
19: 267-275
[Abstract]
Scher, A. I., Stewart, W. F., Lipton, R. B.
(2004). Caffeine as a risk factor for chronic daily headache: A population-based study. Neurology
63: 2022-2027
[Abstract][Full Text]
Jabaudon, D.
(2004). Are Cola Drinkers at Risk of Hypovitaminosis C?. Arch Intern Med
164: 2282-2283
[Full Text]
Happonen, P., Voutilainen, S., Salonen, J. T.
(2004). Coffee Drinking Is Dose-Dependently Related to the Risk of Acute Coronary Events in Middle-Aged Men. J. Nutr.
134: 2381-2386
[Abstract][Full Text]
Lipton, R. B., Bigal, M. E.
(2003). Chronic daily headache: Is analgesic overuse a cause or a consequence?. Neurology
61: 154-155
[Full Text]
Mauskop, A., Katsarava, Z., Fritsche, G., Muessig, M., Diener, H.C., Limmroth, V.
(2002). Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology
58: 1443-1444
[Full Text]
Welch, K. M. A.
(2001). A 47-Year-Old Woman With Tension-type Headaches. JAMA
286: 960-966
[Full Text]
Evans, S. M., Griffiths, R. R.
(1999). Caffeine Withdrawal: A Parametric Analysis of Caffeine Dosing Conditions. J. Pharmacol. Exp. Ther.
289: 285-294
[Abstract][Full Text]
Miller, C. S.
(1999). Are we on the threshold of a new theory of disease? Toxicant-induced loss of tolerance and its relationship to addiction and abdiction. Toxicol Ind Health
15: 284-294
[Abstract]
Fredholm, B. B., Battig, K., Holmen, J., Nehlig, A., Zvartau, E. E.
(1999). Actions of Caffeine in the Brain with Special Reference to Factors That Contribute to Its Widespread Use. Pharmacol. Rev.
51: 83-133
[Abstract][Full Text]
Dager, S. R., Layton, M. E., Strauss, W., Richards, T. L., Heide, A., Friedman, S. D., Artru, A. A., Hayes, C. E., Posse, S.
(1999). Human Brain Metabolic Response to Caffeine and the Effects of Tolerance. Am. J. Psychiatry
156: 229-237
[Abstract][Full Text]
Stein, M. A., Krasowski, M., Leventhal, B. L., Phillips, W., Bender, B. G.
(1996). Behavioral and Cognitive Effects of Methylxanthines: A Meta-analysis of Theophylline and Caffeine. Arch Pediatr Adolesc Med
150: 284-288
[Abstract]
Strain, E. C., Mumford, G. K., Silverman, K., Griffiths, R. R.
(1994). Caffeine Dependence Syndrome: Evidence From Case Histories and Experimental Evaluations. JAMA
272: 1043-1048
[Abstract]
Glass, R. M.
(1994). Caffeine Dependence: What Are the Implications?. JAMA
272: 1065-1066
[Abstract]
Etherton, G. M., Kochar, M. S.
(1993). Coffee: Facts and Controversies. Arch Fam Med
2: 317-322
[Abstract]
(1992). CAFFEINE WITHDRAWAL SYNDROME IS REAL. JWatch General
1992: 5-5
[Full Text]
